Further evaluation of the efficacy of emamectin benzoate for treating Pseudocapillaria tomentosa (Dujardin 1843) in zebrafish Danio rerio (Hamilton 1822). Issue 10 (15th July 2019)

• Record Type: Journal Article
• Authors: Kent, Michael L.; Watral, Virginia; Gaulke, Christopher A.; Sharpton, Thomas J.
• Is Part Of: Journal of fish diseases. Volume 42:Issue 10(2019)
• Page Start: 1351
• Page End: 1357
• Publication Date: 2019-07-15
• Subjects: emamectin benzoate -- Pseudocapillaria tomentosa -- zebrafish Danio rerio; Fishes -- Diseases -- Periodicals; 639.3
• DOI: 10.1111/jfd.13057
• Languages: English
• ISSNs: 0140-7775

Abstract

Abstract: Pseudocapillaria tomentosa is a pathogenic nematode parasite, causing emaciation and severe inflammatory lesions in the intestines in zebrafish Danio rerio (Hamilton 1822). Emamectin benzoate is commercially available analogue of ivermectin used for treating salmon for sea lice, under the brand name SLICE ®, and we have used this for treating zebrafish with the P. tomentosa . Here, SLICE ®, 0.2 per cent active emamectin benzoate, was used for oral treatments at 0.35 mg emamectin benzoate/kg fish/day for 14 days starting at 7 days post‐exposure (dpe). Another experiment entailed initiating treatment during clinical disease (starting at 28 dpe). Early treatment was very effective, but delaying treatment was less so, presumably due to inappetence in clinically affected fish. We evaluated emamectin benzoate delivered in water, using Lice‐Solve™ (mectinsol; 1.4% active emamectin benzoate) in two experiments. Application of four 24‐hr treatments, space over 7 days was initiated at 28 dpe at either 0.168 or 0.56 mg emamectin benzoate/L/bath, and both treatments completely eradicated infections. This was 3 or 10 times manufacture's recommended dose, but was not associated with clinical or histological side effects.